Search
forLearn
5 / 801 resultslearn Metformin
diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties
learn HYDROXYPROPYLGLUCONAMIDE
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn 18β-glycyrrhetinic acid
Research
5 / 284 results
research 557 A peptide derivative with known anti-wrinkle properties was identified as potent dipeptiylpeptidase-4 inhibitor
A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.
research Linagliptin-Associated Alopecia and Bullous Pemphigoid
Linagliptin may cause hair loss and skin blisters.
research Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
Medications for PCOS don't seem to raise heart disease risk.
research Alopecia areata universalis nach Sitagliptin-Einnahme
A patient's hair loss may be linked to their diabetes medication, Sitagliptin.
research Antidiabetic Management Strategies for Treatment of Polycystic Ovarian Syndrome
Combining antidiabetic drugs, hormonal therapies, and lifestyle changes can improve health in women with PCOS.
Community Join
5 / 1000+ resultscommunity Does anyone know of the actual effectiveness of the DP2 inhibitors?
Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.
community PP405 Identity Research
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
community Is PP405 marketed as an alternative to finasteride? Will we no longer need to crush dht?
PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.
community Treating my DUPA via controlling inflammation
The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.